SLC12A2

Solute carrier family 12 member 2 · P55011 · SLC12A2 on Sugi Atlas →

3,812 patent compounds predicted against SLC12A2, 2,701 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4181150	0.50	2/20
Bumetanide (SCHEMBL27525)	1.00	1/20
Bumetanide (SCHEMBL4425232)	1.00	1/20
Bumetanide (SCHEMBL251062)	0.98	1/20
Bumetanide (SCHEMBL2255359)	0.98	1/20
Bumetanide (SCHEMBL250621)	0.96	1/20
Bumetanide (SCHEMBL250723)	0.92	1/20
Bumetanide (SCHEMBL4290796)	0.89	1/20
Bumetanide (SCHEMBL251195)	0.87	1/20
SCHEMBL230651	0.86	1/20
SCHEMBL2742069	0.86	1/20
Bumetanide (SCHEMBL251377)	0.85	1/20
Bumetanide (SCHEMBL251378)	0.85	1/20
SCHEMBL230554	0.84	1/20
SCHEMBL231511	0.84	1/20
SCHEMBL2880587	0.84	1/20
Bumetanide (SCHEMBL229082)	0.84	1/20
Bumetanide (SCHEMBL230683)	0.84	1/20
SCHEMBL231512	0.82	1/20
Bumetanide (SCHEMBL4020472)	0.82	1/20

Clinical trials — most relevant to SLC12A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Intrathecal Gene Therapy For SLC13A5 Citrate Transporter Disorder	PHASE1/PHASE2	NOT_YET_RECRUITING
CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops	PHASE2	UNKNOWN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.	PHASE2	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Bile Acid Effects in Fetal Arrhythmia Study	nan	UNKNOWN
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Effect of SLC01B1 (rs2306283) Polymorphism on the Efficacy and Safety Profile of Atorvastatin in Pakistani Population	nan	COMPLETED
Autonomic Function in Patients With COPD	nan	COMPLETED
Characterization of Breg Cells	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
Gyrate Atrophy Ocular and Systemic Study	nan	ACTIVE_NOT_RECRUITING
Oxalate and Citrate	nan	RECRUITING
Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia	nan	COMPLETED
Genetic Variants and Iron Absorption	nan	COMPLETED
Effect of SLC01B1 (rs4149956) Polymorphism on the Efficacy and Tolerability of Atorvastatin in Pakistani Population	nan	COMPLETED
ADPKD Alterations in Hepatic Transporter Function	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors	nan	UNKNOWN
Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy	nan	COMPLETED
Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients	nan	COMPLETED
Register for Patients With Thyroid Hormone Resistance.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SLC12A2 binder may also engage these)

Protein	Name	Similarity
P55012	—	1.000	P55012 →
P55013	—	0.994	P55013 →
A0A0G2KTI4	—	0.993	A0A0G2KTI4 →
P55014	—	0.987	P55014 →
P55015	—	0.982	P55015 →
Q13621	—	0.982	Q13621 →
P55016	—	0.982	P55016 →
Q9Z1F9	—	0.968	Q9Z1F9 →
Q7ZY60	—	0.965	Q7ZY60 →
UBA2	SUMO-activating enzyme subunit 2	0.965	landscape →
Q67UL3	—	0.964	Q67UL3 →
P49282	—	0.964	P49282 →
Q642Q1	—	0.964	Q642Q1 →
Q2U834	—	0.964	Q2U834 →
E9Q4Z2	—	0.963	E9Q4Z2 →
P48763	—	0.961	P48763 →
ACACB	Acetyl-CoA carboxylase 2	0.961	landscape →
P58421	—	0.961	P58421 →
Q9QW07	—	0.961	Q9QW07 →
A2R0Z5	—	0.960	A2R0Z5 →
Q0IQA5	—	0.960	Q0IQA5 →
Q9S7Z8	—	0.960	Q9S7Z8 →
Q07722	—	0.960	Q07722 →
PI4KB	Phosphatidylinositol 4-kinase beta	0.960	landscape →
Q3ZAS0	—	0.960	Q3ZAS0 →
Q2HXL0	—	0.960	Q2HXL0 →
G2XEK6	—	0.960	G2XEK6 →
Q5ZJH9	—	0.959	Q5ZJH9 →
O02810	—	0.959	O02810 →
P50482	—	0.959	P50482 →